[Aflibercept: focus on tolerability.]
Aflibercept, a potent antiangiogenic agent that exhibits a broad spectrum of antitumor activity, is currently administered in combination with FOLFIRI for the second-line treatment of metastatic colorectal cancer. Here, practical measures to minimize the risk of toxicity in real-world patients are suggested.